Clinical Trial Update: A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle [Phase 3]

View source ↗

Summary

Vericel's MACI is being studied in a Phase 3 trial for symptomatic chondral or osteochondral defects of the ankle in patients aged 17 to 65. The study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chondral Defect of the Ankle
• Osteochondral Defect of the Ankle

Drugs mentioned

• MACI (matrix-induced autologous chondrocyte implantation)

Snippet

Sponsor: Vericel Corporation | Conditions: Chondral Defect, Articular Cartilage Defect | Phase 3 | Status: RECRUITING